ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.

Humans DNA-Binding Proteins / genetics Transcription Factors / genetics Nuclear Proteins / genetics Prognosis Lung Neoplasms / drug therapy Mutation ErbB Receptors / genetics Biology
ARID1A SWI/SNF complex cell cycle regulation epithelial–mesenchymal transition lung cancer metabolic reprogramming

Journal

Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 06 04 2023
revised: 20 04 2023
accepted: 21 04 2023
medline: 17 7 2023
pubmed: 14 5 2023
entrez: 13 5 2023
Statut: ppublish

Résumé

Mutations in the AT-interacting domain-rich protein 1A (ARID1A) gene, a critical component of the switch/sucrose nonfermentable (SWI/SNF) complex, are frequently found in most human cancers. Approximately 5-10% of lung cancers carry ARID1A mutations. ARID1A loss in lung cancer correlates with clinicopathological features and poor prognosis. Co-mutation of ARID1A and epidermal growth factor receptor (EGFR) results in the limited efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) but increases the clinical benefit of immune checkpoint inhibitors (ICIs). ARID1A gene mutation plays a role in cell cycle regulation, metabolic reprogramming, and epithelial-mesenchymal transition. We present the first comprehensive review of the relationship between ARID1A gene mutations and lung cancer and discuss the potential of ARID1A as a new molecular target.

Identifiants

DOI: 10.1016/j.molmed.2023.04.005 PMID: 37179132
pubmed: 37179132
pii: S1471-4914(23)00075-8
doi: 10.1016/j.molmed.2023.04.005
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
Transcription Factors 0
Nuclear Proteins 0
ErbB Receptors EC 2.7.10.1
ARID1A protein, human 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-658

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests S.L. has received research support from BerGenBio, Bristol Myers Squibb, Eli Lilly and Company, Roche, and ADC Therapeutics. S.L. has received speaker honoraria from BerGenBio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Roche, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda Pharmaceutical Company, Amgen, Bayer, Janssen Pharmaceuticals, and Merck. S.L. is consultant to BerGenBio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Roche, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda Pharmaceutical Company, Amgen, Bayer, Janssen Pharmaceuticals, and Merck. S.L. has received travel support from BerGenBio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Roche, Medac, Sanofi Aventis, Novartis, AstraZeneca, Pfizer, Takeda Pharmaceutical Company, Amgen, Bayer, Janssen Pharmaceuticals, and Merck. Author S.L. has received drugs for research from Bristol Myers Squibb. All other authors have no financial or any other competing interests.

Auteurs

Fukang Jin (F)

JCCU Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Zhiguang Yang (Z)

Department of Thoracic Surgery, The First Hospital of Jilin University, Jilin, China.

Jingbo Shao (J)

Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Jianxin Tao (J)

JCCU Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Christoph Reißfelder (C)

DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Sonja Loges (S)

DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Personalized Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Lei Zhu (L)

JCCU Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: lei.zhu@dkfz.de.

Sebastian Schölch (S)

JCCU Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ-Hector Cancer Institute, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: s.schoelch@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de liaison à l'ADN › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Diagnostic › Pronostic › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › ARID1A mutations in lung cancer: biology,...
questionsmedicales.fr › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Biologie › ARID1A mutations in lung cancer: biology,...